Endo M. Construction of heavy ion accelerator in Chiba (HIMAC) and its consequences—from medical physics viewpoint: part 1. Period until treatment Start (1975–1994). Jpn J Med Phys. 2020;40:61–7 (in Japanese).
Endo M. Construction of Heavy Ion Accelerator in Chiba (HIMAC) and its consequences—from medical physics viewpoint: part 2. Advancement of broad beam irradiation and development of a new compact-sized therapy accelerator (1994–2010). Jpn J Med Phys. 2020;40:97–105 (in Japanese).
Endo M. Construction of Heavy Ion Accelerator in Chiba (HIMAC) and its consequences—from medical physics viewpoint: part 3. Development of scanning irradiation and construction of new facility (2006–). Jpn J Med Phys. 2020;40:126–38 (in Japanese).
Endo M. Construction of Heavy Ion Accelerator in Chiba (HIMAC) and its consequences—from medical physics viewpoint: part 4. Outline of clinical research and future prospects. Jpn J Med Phys. 2021;41:10–21 (in Japanese).
Endo M. Creation, evolution, and future challenges of ion beam therapy from a medical physicist’s viewpoint (Part 1). Introduction and Chapter 1. Accelerator and beam delivery system. Radiol Phys Technol. 2022;15:271–90.
Endo M. Creation, evolution, and future challenges of ion beam therapy from a medical physicist’s viewpoint (Part 2)—Chapter 2. Bio-physical model and treatment planning system. Radiol Phys Technol. 2023;16:137–59.
International Commission on Radiation Units and Measurements. ICRU Report 93. Prescribing, recording, and reporting light ion beam therapy. J ICRU. 2019;16(1–2). https://www.icru.org/report/icru-report-93-prescribing-recording-and-reporting-light-ion-beam-therapy/. Accessed 27 Sept 2023.
Endo M. Robert R. Wilson (1914–2000): the first scientist to propose particle therapy—use of particle beam for cancer treatment. Radiol Phys Technol. 2018;11:1–6.
Alonso JR, Castro JR. light-ion therapy in the US: from the Bevalac to??. In: XVI Congress of Health Econometrics of the IAEA, Ajaccio, France, 9–11 Oct 2002. https://www.osti.gov/servlets/purl/803872. Accessed 23 Oct 2023.
Particle therapy cooperation group. Patient statistics. https://ptcog.site/images/Statistics/Patientstatistics-updateDec2021Sep6.2022provisional.pdf. Accessed 27 Sept 2023.
Linstadt DE, Castro JR, Philips T. Neon ion radiotherapy: results of the phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 1991;20:761–9.
Article CAS PubMed Google Scholar
Castro JR, Linstadt DE, Bahary J-P, et al. Experience in charge particle irradiation of tumors of the skull base: 1977–1992. Int J Radiat Oncol Biol Phys. 1994;29:647–55.
Article CAS PubMed Google Scholar
Munzenrider JE, Austin-Seymour M, Blitzer PJ, et al. Proton therapy at Harvard. Strahlentherapie. 1985;161:756–63.
Austin-Seymour M, Munzenrider J, Goitein M, et al. Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull. J Neurosurg. 1989;70:13–7.
Article CAS PubMed Google Scholar
Austin-Seymour M, Munzenrider JE, Goitein M, et al. Progress in low LET heavy particle therapy: intracranial and paracranial tumors and uveal melanomas. Radiat Res. 1985;104:S219–26.
Slater JD, Yonemoto LT, Rossi CJ Jr, et al. Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998;42:299–304.
Article CAS PubMed Google Scholar
Fukumoto S. Proton beam therapy at Tsukuba. Proc of a Medical Workshop on Accelerators for Charged-Particle Beam Therapy, pp. 1–5, Fermilab, January 1985. https://lss.fnal.gov/conf/C850125/pg1.pdf. Accessed 23 Oct 2023.
Tsuji H, Tsujii H, Okumura T, et al. Preliminary results of proton radiotherapy at the Proton Medical Research Center, Tsukuba. J JASTRO. 1995;7:303–13. https://doi.org/10.11182/jastro1989.7.303 (in Japanese).
Tsujii T. Radiotherapy Research. In: National Institute of Radiological Sciences (NIRS), editor. 50-year history of the National Institute of Radiological Sciences. Chiba: NIRS; 2007. p. 155–205 (in Japanese).
Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet. 1998;351:1242–5.
Article CAS PubMed Google Scholar
Withers HR, Taylor JMG, Maciejewski B. Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys. 1998;14:751–9.
Ando K, Koike S, Nojima K, et al. Mouse skin damages caused by fractionated irradiation with carbon ions. Int J Radiat Biol. 1998;74:129–38.
Article CAS PubMed Google Scholar
Koike S, Ando K, Oohara C, et al. Relative biological effectiveness of 290 MeV/u carbon ions for the growth delay of a radioresistant murine fibrosarcoma. J Radiat Res. 2002;43:247–55.
Ando K, Koike S, Uzawa A, et al. Biological gain of carbon-ion radiotherapy for the early response of tumor growth delay and against early response of skin reaction in mice. J Radiat Res. 2005;46:51–7.
Japanese Society for Radiation Oncology: Indications and unified treatment policy for particle beam therapy (proton beam therapy, heavy ion beam therapy) as advanced medical care. 2016. https://www.jastro.or.jp/medicalpersonnel/particle_beam/2016/02/post-2.html. Accessed 27 Sept 2023 (in Japanese).
Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1027–38.
Article CAS PubMed Google Scholar
Koto M, Demizu Y, Saitoh JI, et al. Japan Carbon-ion Radiation Oncology Study Group, Multicenter study of carbon-ion radiation therapy for mucosal melanoma of the head and neck: Subanalysis of the Japan Carbon-ion Radiation Oncology Study Group study. Int J Radiat Oncol Biol Phys. 2017;97:1054–60.
Sulaiman NS, Demizu Y, Koto M, et al. Multicenter study of carbon-ion radiation therapy for adenoid cystic carcinoma of the head and neck: subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). Int J Radiat Oncol Biol Phys. 2018;100:639–46.
Matsunobu A, Imai R, Kamada T, et al. Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer. 2012;118:4555–63.
Imai R, Kamada T, Araki N, Abe S, et al. Working Group for Bone and Soft Tissue Sarcomas, Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases. Int J Radiat Oncol Biol Phys. 2016;295:322–7.
Yolcu YU, Jad Z, Wahood W, et al. Comparison of oncologic outcomes and treatment-related toxicity of carbon ion radiotherapy and en Bloc resection for sacral chordoma. JAMA Network Open. 2022;5(1):e2141927.
Article PubMed PubMed Central Google Scholar
Japan Society for Head and Neck Cancer. Report of head and neck cancer registry of Japan—clinical statistics of registered patients, 2019. 2022. http://www.jshnc.umin.ne.jp. HNCreport_2019. Accessed 27 Sept 2023.
National Cancer Center. Cancer type statistical information. https://ganjoho.jp/reg_stat/statistics/stat/cancer/index.html. Accessed 27 Sept 2023 (in Japanese).
National Cancer Center. Description of various rare cancers. https://www.ncc.go.jp/jp/rcc/about/. Accessed 27 Sept 2023 (in Japanese).
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Miyamoto T, Baba M, Yamamoto N, et al. Curative treatment of stage I non-small-cell lung cancer with carbon ion beams using a hypo-fractionated regimen. Int J Radiat Oncol Biol Phys. 2007;67:750–8.
Article CAS PubMed Google Scholar
Miyamoto T, Baba M, Sugane T, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol. 2007;2:916–26.
Yamamoto N, Miyamoto T, Nakajima M, et al. A dose escalation clinical trial of single-fraction carbon ion radiotherapy for peripheral stage I non-small cell lung cancer. J Thorac Oncol. 2017;12:673–80.
Ono T, Yamamoto N, Nomoto A, et al. Long term results of single-fraction carbon-ion radiotherapy for non-small cell lung cancer. Cancers (Basel). 2021;13(1):112.
Siva S, Ball DL. Single fraction SBRT for early stage lung cancer—less is more? Int J Radiat Oncol Biol Phys. 2019;103:1085–7.
Endo M. History of medical physics. Radiol Phys Technol. 2021;14:345–57.
Nagata Y, Hiraoka M, Shibata T, et al. A Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93:989–96.
Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81:1352–8.
Ohnishi K, Nakamura N, Harada H, et al. Proton beam therapy for histologically or clinically diagnosed stage I non-small cell lung cancer (NSCLC): the first nationwide retrospective study in Japan. Int J Radiat Oncol Biol Phys. 2020;106:82–9.
Article CAS PubMed Google Scholar
Okami J, Shintani Y, Okumura M, et al. Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010. J Thorac Oncol. 2019;14:212–22.
Anzai M, Yamamoto N, Hayashi K, et al. Safety and efficacy of carbon-ion radiotherapy alone for stage ΙΙΙ non-small cell lung cancer. Anticancer Res. 2020;40:379–86.
Article CAS PubMed Google Scholar
Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;162:187–99.
Comments (0)